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The current standard therapy for chronic hepatitis C virus 
(HCV) infection is the combination of pegylated interferon 
and ribavirin. The ultimate goal of treatment in patients with 
chronic HCV infection is to completely eradicate HCV in 
infected hosts, and prevent liver-related morbidity and 
mortality. However, these goals are difficult to measure and 
it takes long time to assess the achievement of these goals. A 
sustained virologic response (SVR) has been used as a 
surrogate marker of these ultimate goals in treatment of 
chronic hepatitis C. An SVR is defined as undetectable 
serum HCV RNA at 24 weeks after the end of treatment. To 
be a useful surrogate marker, achievement of SVR should 
result in the reduction of liver-related morbidity and mortality, 
complete eradication of HCV in infected hosts, and no late 
virologic relapse. 
Achievement of SVR has been associated with improvement 
in liver histology and health-related quality of life, as well as 
a reduced risk of hepatocellular carcinoma and liver-related 
mortality.
1-3 The survival of patients who achieved SVR was 
reported to be comparable to that of general population, 
matched for age and sex.
4 However, the development of 
hepatocellular carcinoma was reported despite achievement 
of SVR in patients with chronic hepatitis C and advance 
fibrosis.
5
There is some debate as to whether achievement of SVR 
results in complete eradication of HCV. In a study of 2089 
patients with chronic hepatitis C from 3 clinical trials, hepatic 
HCV RNA was found to correlate with serum HCV RNA in 
all cases, and 98% of sustained virologic responders had 
undetectable hepatic HCV RNA.
6 Several small studies have 
described patients who achieved SVR but have residual 
HCV RNA detected in peripheral blood mononuclear cells 
with highly sensitive reverse transcription and nested 
polymerase chain reaction assays.
7,8 Whether these findings 
represent a replication-competent virus or have any clinical 
significance is unclear. 
Several small studies reported SVR achieved with con-
ventional interferon alone or in combination with ribavirin 
was durable. In these reports, serum HCV RNA remained 
undetectable in 92-100% of patients who achieved SVR 
with 2 to 13 years of follow-up.
4,5,9-12 However, there are 
limited data on the durability of SVR achieved with 
peginterferon in patients with chronic hepatitis C. Swain et 
al. studied the durability of SVR achieved with peginterferon 
in 1343 patients.
13 They analyzed the durability of SVR in 
large cohort of patients who were enrolled in one of 9 
randomized controlled clinical trials,
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the efficacy of peginteferon alfa-2a alone or in combination 
with ribavirin. Total 1343 treatment-naïve patients who 
achieved SVR and had at least one post-baseline HCV RNA 
evaluation were assessed. One thousand three hundred thirty 
one of 1343 patients (99.1%) remained HCV RNA undete-
ctable in serum at mean of 3.9 years after completion of 
treatment. The durability of SVR in this study was independent 
of patient characteristics such as HCV mono-infection, 
HCV-HIV co-infection, or ALT level. The durability of SVR 
also appeared to be unaffected by the type of treatment. 
HCV RNA was detected in the serum of 12 patients who 
obtained SVR in their original studies at mean of 666 days 
after completing treatment. Among the 12 patients with 
reappearance of HCV RNA, there were no baseline or 
treatment factors associated with reappearance of HCV 
RNA including HCV genotype, sex, age, race, risk factor for 
infection, or baseline viral load. It was unknown whether 
these cases reflect relapse or re-infection because of the 
paucity of paired samples. The findings of this study were 
comparable with those reported from smaller studies with 
conventional interferon. 
There was one domestic report on the durability of 
interferon-based therapy in patients with chronic hepatitis 
C.
23 In this study, 73 patients who achieved SVR with 
conventional interferon or peginterferon in combination 
with ribavirin were included. HCV RNA reappeared in 8 of 
73 (11%), but persistent viremia remained only in one 
patient (1.4%). Transient positive tests probably represent 
false-positive test, and the durability of SVR in Korean 
patients with chronic hepatitis C appears to be similar with 
those reported in other studies. 
In conclusion, this study showed SVR achieved with 
peginterferon alfa-2a alone or in combination with ribavirin 
is durable in 99% of patients for at least 4 years after completion 
of therapy and is independent of patient or treatment 
characteristics. 
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